246 related articles for article (PubMed ID: 23458961)
1. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
[TBL] [Abstract][Full Text] [Related]
2. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
3. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
[TBL] [Abstract][Full Text] [Related]
4. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
5. Yellow fever vaccine: an effective vaccine for travelers.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
[TBL] [Abstract][Full Text] [Related]
6. Late vaccination against yellow fever of travelers visiting endemic countries.
Krief I; Goldblatt JG; Paz A; Potasman I
Travel Med Infect Dis; 2006 Mar; 4(2):94-8. PubMed ID: 16887731
[TBL] [Abstract][Full Text] [Related]
7. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
Jentes ES; Poumerol G; Gershman MD; Hill DR; Lemarchand J; Lewis RF; Staples JE; Tomori O; Wilder-Smith A; Monath TP;
Lancet Infect Dis; 2011 Aug; 11(8):622-32. PubMed ID: 21798462
[TBL] [Abstract][Full Text] [Related]
8. The elderly, the young and the pregnant traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination.
Jaeger VK; Tschudi N; Rüegg R; Hatz C; Bühler S
Travel Med Infect Dis; 2015; 13(6):475-84. PubMed ID: 26526774
[TBL] [Abstract][Full Text] [Related]
9. Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011.
LaRocque RC; Rao SR; Lee J; Ansdell V; Yates JA; Schwartz BS; Knouse M; Cahill J; Hagmann S; Vinetz J; Connor BA; Goad JA; Oladele A; Alvarez S; Stauffer W; Walker P; Kozarsky P; Franco-Paredes C; Dismukes R; Rosen J; Hynes NA; Jacquerioz F; McLellan S; Hale D; Sofarelli T; Schoenfeld D; Marano N; Brunette G; Jentes ES; Yanni E; Sotir MJ; Ryan ET;
Clin Infect Dis; 2012 Feb; 54(4):455-62. PubMed ID: 22144534
[TBL] [Abstract][Full Text] [Related]
10. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
13. Prevention of yellow fever in persons traveling to the tropics.
Monath TP; Cetron MS
Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
15. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
16. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
[TBL] [Abstract][Full Text] [Related]
17. Adverse events following yellow fever vaccination in immunocompromised persons.
Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
[TBL] [Abstract][Full Text] [Related]
18. The response to re-emergence of yellow fever in Nigeria, 2017.
Nwachukwu WE; Yusuff H; Nwangwu U; Okon A; Ogunniyi A; Imuetinyan-Clement J; Besong M; Ayo-Ajayi P; Nikau J; Baba A; Dogunro F; Akintunde B; Oguntoye M; Kamaldeen K; Fakayode O; Oyebanji O; Emelife O; Oteri J; Aruna O; Ilori E; Ojo O; Mba N; Nguku P; Ihekweazu C
Int J Infect Dis; 2020 Mar; 92():189-196. PubMed ID: 31935537
[TBL] [Abstract][Full Text] [Related]
19. Yellow fever: epidemiology and prevention.
Barnett ED
Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
[TBL] [Abstract][Full Text] [Related]
20. Global Risk and Elimination of Yellow Fever Epidemics.
Ndeffo-Mbah ML; Pandey A
J Infect Dis; 2020 Jun; 221(12):2026-2034. PubMed ID: 31545372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
